The effects of additional treatment with terguride, a partial dopamine agonist, on hyperprolactinemia induced by antipsychotics in schizophrenia patients: a preliminary study

References

• ByerlyMSuppesTTranQVBakerRAClinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectivesJ Clin Psychopharmacol200727663966118004132
   PubMed Web of Science ®Google Scholar
• BostwickJRGuthrieSKEllingrodVLAntipsychotic-induced hyperprolactinemiaPharmacotherapy2009291647319113797
   PubMed Web of Science ®Google Scholar
• MeaneyAMSmithSHowesODO’BrienMMurrayRMO’KeaneVEffects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophreniaBr J Psychiatry200418450350815172944
   PubMed Web of Science ®Google Scholar
• CostaAMLimaMSMari JdeJA systematic review on clinical management of antipsychotic-induced sexual dysfunction in schizophreniaSao Paulo Med J2006124529129717262163
   PubMedGoogle Scholar
• WachtelHDorowRDual action on central dopamine function of transdihydrolisuride, a 9,10-dihydrogenated analogue of the ergot dopamine agonist lisurideLife Sci19833244214326827903
   PubMed Web of Science ®Google Scholar
• KehrWTransdihydrolisuride, a partial dopamine receptor antagonist: effects on monoamine metabolismEur J Pharmacol1984971–21111196421606
   PubMed Web of Science ®Google Scholar
• StephensDNLöschmannPALanzingerCWachtelHMontgomeryAMHerbergLJUnusual interactions between the neuroleptic haloperidol, and the dopamine D2 partial agonist, tergurideBehav Pharmacol19901652152911175438
   PubMedGoogle Scholar
• YamaguchiMKimura-IwasakiKAkaiTNakadaYNakagawaHTerguride, a dopamine D(2) partial agonist, as a discriminative stimulus in ratsBehav Pharmacol19912323324011224067
   PubMed Web of Science ®Google Scholar
• WachtelHDorowRSauerGNovel 8 alpha-ergolines with inhibitory and stimulatory effects on prolactin secretion in ratsLife Sci19843518185918676492995
   PubMed Web of Science ®Google Scholar
• LingjaerdeOAhlforsUGBechPDenckerSJElgenKThe UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patientsActa Psychiatr Scand Suppl198733411002887090
   PubMedGoogle Scholar
• VenturiniPLHorowskiRValenzanoMEffect of terguride on prolactin levels in normal, puerperal and hyperprolactinaemic womenEur J Clin Pharmacol19863021951973709645
   PubMed Web of Science ®Google Scholar
• CiccarelliETouzelRBesserMGrossmanATerguride – a new dopamine agonist drug: a comparison of its neuroendocrine and side effect profile with bromocriptineFertil Steril19884945895943127243
   PubMed Web of Science ®Google Scholar
• VĕtrMTalasMPohankaJGazárekFFingerováHTerguride in the treatment of hyperprolactinemiaActa Univ Palacki Olomuc Fac Med19901251551602150271
   PubMedGoogle Scholar
• KaneJMCarsonWHSahaAREfficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorderJ Clin Psychiatry200263976377112363115
   PubMed Web of Science ®Google Scholar
• CaseyDECarsonWHSahaARAripiprazole Study Group. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized studyPsychopharmacology (Berl)2003166439139912610718
   PubMed Web of Science ®Google Scholar
• MarderSRMcQuadeRDStockEAripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trialsSchizophr Res2003612–312313612729864
   PubMed Web of Science ®Google Scholar
• LinSKChenCKReversal of antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole: a case reportJ Clin Psychiatry2006678130716965214
   PubMed Web of Science ®Google Scholar
• WahlROstroffRReversal of symptomatic hyperprolactinemia by aripiprazoleAm J Psychiatry200516281542154316055781
   PubMed Web of Science ®Google Scholar
• LeeBHKimYKParkSHUsing aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot studyProg Neuropsychopharmacol Biol Psychiatry200630471471716571367
   PubMed Web of Science ®Google Scholar
• WolfJFiedlerUHyperprolactinemia and amenorrhea associated with olanzapine normalized after addition of aripiprazoleJ Clin Pharm Ther200732219719817381670
   PubMed Web of Science ®Google Scholar
• ShimJCShinJGKellyDLAdjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trialAm J Psychiatry200716491404141017728426
   PubMed Web of Science ®Google Scholar
• ChenCHHuangMCLuMLAripiprazole resolves symptomatic hyperprolactinemia in a male schizophrenic patientProg Neuropsychopharmacol Biol Psychiatry200832389389418082301
   PubMed Web of Science ®Google Scholar
• LuMLShenWWChenCHTime course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazoleProg Neuropsychopharmacol Biol Psychiatry20083281978198118848860
   PubMed Web of Science ®Google Scholar
• MirAShivakumarKWilliamsonRJMcAllisterVO’KeaneVAitchisonKJChange in sexual dysfunction with aripiprazole: a switching or add-on studyJ Psychopharmacol200822324425318308789
   PubMed Web of Science ®Google Scholar
• SheldrickAJGründerGAripiprazole reduces serum prolactin in a woman with prolactinoma and acute psychosisPharmacopsychiatry200841416018651348
   PubMed Web of Science ®Google Scholar
• ByerlyMJMarcusRNTranQVEudiconeJMWhiteheadRBakerRAEffects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label studySchizophr Res20091072–321822219038534
   PubMed Web of Science ®Google Scholar
• Yasui-FurukoriNKanedaASugawaraNTomitaTKanekoSEffect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patientsJ Psychopharmacol201226680681221616975
   PubMed Web of Science ®Google Scholar
• Yasui-FurukoriNFurukoriHSugawaraNFujiiAKanekoSDose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophreniaJ Clin Psychopharmacol201030559659920814333
   PubMed Web of Science ®Google Scholar
• HoriHYoshimuraRKatsukiASugitaAIAtakeKNakamuraJSwitching to antipsychotic monotherapy can improve attention and processing speed, and social activity in chronic schizophrenia patientsJ Psychiatr Res201347121843184824054464
   PubMed Web of Science ®Google Scholar
• TadoriYMiwaTTottoriKAripiprazole’s low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychoticEur J Pharmacol20055151–3101915894311
   PubMed Web of Science ®Google Scholar
• TadoriYKitagawaHForbesRAMcQuadeRDStarkAKikuchiTDifferences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912Eur J Pharmacol20075742–310311117692841
   PubMed Web of Science ®Google Scholar
• UrichukLPriorTIDursunSBakerGMetabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug–drug interactionsCurr Drug Metab20089541041818537577
   PubMed Web of Science ®Google Scholar